<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41826" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cilostazol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Balinski</surname>
            <given-names>Alexander M.</given-names>
          </name>
          <aff>Oakland University William Beaumont School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexander Balinski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41826.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cilostazol is a quinolone derivative primarily used to treat intermittent claudication due to peripheral vascular disease, the FDA-approved indication. Cilostazol is also indicated for secondary prevention in patients with a history of transient ischemic attacks or non-cardioembolic ischaemic stroke. Cilostazol improves walking distance by promoting vasodilation and antiplatelet activity with inhibition of phosphodiesterase III and subsequent increases in available cAMP. This activity reviews the indications, contraindications, and use of cilostazol and highlights the role of the interprofessional team in monitoring the adverse effects of the drug.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanisms of action of cilostazol.</p></list-item><list-item><p>Describe the adverse effects of cilostazol.</p></list-item><list-item><p>Review and select appropriate monitoring of cilostazol.</p></list-item><list-item><p>Summarize how the interprofessional team can collaborate to optimize therapeutic results with cilostazol.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41826&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41826">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41826.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Cilostazol&#x000a0;is a&#x000a0;quinolone derivative&#x000a0;and is FDA approved for the treatment of intermittent claudication associated with early-stage peripheral&#x000a0;vascular disease.<xref ref-type="bibr" rid="article-41826.r1">[1]</xref>&#x000a0;Intermittent claudication is caused by the narrowing of arteries that supply the legs with oxygenated blood. Patients with intermittent claudication develop pain when walking due to a lack of oxygen-containing blood reaching the operating leg muscles. Cilostazol decreases the pain of intermittent claudication by dilating these arteries, which improves blood flow and oxygen to the legs.&#x000a0;Cilostazol&#x000a0;is an effective therapy for improving walking distances in patients with intermittent claudication, and the artery disease guidelines of the American College of Cardiology/American Heart Association reference a therapeutic trial of cilostazol.<xref ref-type="bibr" rid="article-41826.r2">[2]</xref>[Level I]</p>
        <p>Cilostazol has also been&#x000a0;used off-labeled for the long-term prevention of severe vascular events in patients with a history of transient ischemic attack or non-cardioembolic ischemic stroke.<xref ref-type="bibr" rid="article-41826.r3">[3]</xref>&#x000a0;Cilostazol is also&#x000a0;used off-labeled for percutaneous coronary intervention (PCI,&#x000a0;following elective stent placement).<xref ref-type="bibr" rid="article-41826.r4">[4]</xref></p>
      </sec>
      <sec id="article-41826.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cilostazol is a phosphodiesterase III (PDE3) inhibitor. PDE3s are&#x000a0;enzymes that utilize a catalytic core to hydrolyze cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP).<xref ref-type="bibr" rid="article-41826.r5">[5]</xref>&#x000a0;Phosphodiesterase III enzymes are primarily located within the cardiac sarcoplasmic reticulum and in the smooth muscle of arteries and veins, where they regulate cardiac and vascular smooth muscle contractility. Cilostazol exerts its action by inhibiting phosphodiesterase activity and suppressing cAMP degradation. The inhibition of PDE3 allows for a rise in&#x000a0;cAMP in platelets and blood vessels. Increased concentrations of cAMP subsequently lead to increase concentrations of the active form of protein kinase A (PKA), and increased PKA is directly related to the inhibition of platelet aggregation.<xref ref-type="bibr" rid="article-41826.r6">[6]</xref>&#x000a0;Elevated concentrations of intracellular PKA also elicit a vasodilatory effect on smooth muscle cells by preventing contraction through the inactivation of myosin light-chain kinase.<xref ref-type="bibr" rid="article-41826.r7">[7]</xref>&#x000a0;</p>
        <p>Myosin light-chain kinase&#x000a0;normally phosphorylates the light chain of myosin in the presence of&#x000a0;calcium and calmodulin, which&#x000a0;activates myosin to interact with actin. With the inactivation of myosin light-chain kinase by PKA, the myosin-actin interaction cannot occur, and&#x000a0;thus, there is&#x000a0;an inability to generate a smooth muscle contraction.<xref ref-type="bibr" rid="article-41826.r8">[8]</xref></p>
        <p>Cilostazol has also recently been demonstrated to reduce plasma triglycerides and increase HDL cholesterol concentrations.<xref ref-type="bibr" rid="article-41826.r9">[9]</xref>&#x000a0;The precise mechanisms of cilostazol's ability to lower plasma triglycerides and increase HDL are&#x000a0;currently not understood; however, the lipoprotein effects of cilostazol are likely a result of the inhibition of cyclic nucleotide phosphodiesterase with a precipitant elevation of intracellular cAMP. As of now, several possible mechanisms have been proposed by which increased cAMP&#x000a0;could result in lowered plasma triglycerides. One possible&#x000a0;explanation is the reduction of hepatic triglyceride secretion (either directly or indirectly) by the increased effectiveness of&#x000a0;glucagon in inhibiting VLDL secretion.<xref ref-type="bibr" rid="article-41826.r10">[10]</xref>&#x000a0;Alternatively, increased cAMP intracellular concentrations have&#x000a0;demonstrated the ability to promote the release of lipoprotein lipase from rat adipocytes,&#x000a0;which could also result in reduced plasma triglycerides.<xref ref-type="bibr" rid="article-41826.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Cilostazol is absorbed after oral administration. A high-fat meal increases absorption, with an approximately 90% increase in&#x000a0;peak serum concentration and a 25% increase in plasma concentration of&#x000a0;the drug&#x000a0;over time.<xref ref-type="bibr" rid="article-41826.r12">[12]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;Cilostazol is 95% to 98% protein-bound, predominantly to albumin. The free fraction of cilostazol&#x000a0;is 27% higher in subjects with renal impairment than in healthy volunteers.</p>
        <p><bold>Metabolism:&#x000a0;</bold>Cilostazol metabolism occurs extensively in&#x000a0;the liver by hepatic cytochrome P450 enzymes (mainly CYP3A4 and, to a lesser extent, CYP2C19). Two metabolites are primarily active, with one appearing to account for at least half of the pharmacologic activity (PDE3 inhibition) after the administration of the drug</p>
        <p><bold>Excretion:&#x000a0;</bold>Cilostazol is predominately eliminated by urinary excretion of metabolites (74%), with the remainder being excreted fecally (20%).<xref ref-type="bibr" rid="article-41826.r13">[13]</xref></p>
      </sec>
      <sec id="article-41826.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Cilostazol is available in 50 mg and 100 mg tablets. It can be dosed and administered for the following conditions. Cilostazol should be administered orally with water 30 minutes before or 2 hours after meals (breakfast and dinner).&#x000a0;Do not&#x000a0;take cilostazol with grapefruit juice, which may impair drug metabolism.<xref ref-type="bibr" rid="article-41826.r14">[14]</xref>&#x000a0;Peak pharmacodynamic effects (increased heart rate, antiplatelet activity, decrease in diastolic blood pressure) usually occur within 6 hours.<xref ref-type="bibr" rid="article-41826.r15">[15]</xref>&#x000a0;Patients may experience symptomatic relief of intermittent claudication within&#x000a0;two to four weeks; however, it can take 12 weeks to&#x000a0;obtain&#x000a0;the optimal therapeutic effect. The dose of&#x000a0;cilostazol can be reduced or discontinued without a rebound phenomenon.</p>
        <p>
<bold>Intermittent Claudication</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>100 mg orally twice daily.</p>
          </list-item>
          <list-item>
            <p>50 mg orally twice daily should be considered during the coadministration of CYP3A4 inhibitors such as diltiazem, erythromycin, ketoconazole, and itraconazole, and during coadministration of CYP2C19 inhibitors such as omeprazole.</p>
          </list-item>
        </list>
        <p>
<bold>Thrombotic Complications of Coronary Angioplasty</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>100 mg orally twice daily can be substituted for either aspirin or clopidogrel as part of a dual antiplatelet regimen in patients with coronary artery stents who have an allergy or intolerance to aspirin or clopidogrel.</p>
          </list-item>
        </list>
        <p><bold>Secondary Prevention of Non-cardioembolic Stroke or TIA(off-label use)</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>100 mg orally twice daily (first-line drugs are aspirin and clopidogrel).<xref ref-type="bibr" rid="article-41826.r16">[16]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Use in Special Population</bold>
</p>
        <p><bold>Hepatic Impairment:&#x000a0;</bold>The pharmacokinetic parameters of cilostazol and its metabolites are similar in healthy subjects compared to subjects with mild hepatic diseases. The use of cilostazol in patients with moderate/severe hepatic impairment is not analyzed.</p>
        <p><bold>Renal Impairment: </bold>The pharmacologic activity of cilostazol and its metabolites was similar in healthy subjects compared to subjects with mild to moderate renal impairment. In patients with severe renal impairment, metabolite levels are increased, altering the protein binding. However, the expected pharmacologic activity based on plasma concentrations and relative PDE III inhibiting potency of parent drug and metabolites appeared little changed.&#x000a0;</p>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>Teratogenic Effects:&#x000a0;Pregnancy Category C.&#x000a0;Cilostazol is teratogenic in rats at doses fivefold the human maximum recommended human dose on a body surface area basis. There are no adequate and well-controlled studies on pregnant women.</p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Because there is no information on using cilostazol during breastfeeding, an alternate drug may be preferred, especially while nursing a preterm infant or newborn. If a nursing mother uses it, monitor the infant for bruising and bleeding.<xref ref-type="bibr" rid="article-41826.r17">[17]</xref></p>
      </sec>
      <sec id="article-41826.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Cilostazol is a generally well-tolerated oral medication. Common side effects of cilostazol therapy reportedly include headache (34%), diarrhea (19%), and palpitations (10%).<xref ref-type="bibr" rid="article-41826.r18">[18]</xref></p>
        <p>A&#x000a0;slight&#x000a0;elevation in heart rate&#x000a0;of 5 to 7 beats/min may also occur with the administration of cilostazol. These side effects are&#x000a0;mild to moderate in intensity, transient, or&#x000a0;alleviated&#x000a0;with symptomatic treatment and seldom demand treatment withdrawal.<xref ref-type="bibr" rid="article-41826.r13">[13]</xref>&#x000a0;Cilostazol may induce tachycardia, tachyarrhythmia, and hypotension.<xref ref-type="bibr" rid="article-41826.r19">[19]</xref></p>
        <p>Postmarketing research has shown cilostazol to induce thrombocytopenia or leukopenia, progressing to agranulocytosis when drug administration does not immediately discontinue. Agranulocytosis is reversible with immediate discontinuation of the drug.<xref ref-type="bibr" rid="article-41826.r20">[20]</xref></p>
      </sec>
      <sec id="article-41826.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p><bold>Box Warning</bold>: According to the manufacturer's labeling, Cilostazol administration is contraindicated in patients with heart failure of any grade. Cilostazol and many of its metabolites are inhibitors of phosphodiesterase III. Several drugs with the pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure.<xref ref-type="bibr" rid="article-41826.r21">[21]</xref></p>
        <p>Drugs with vasodilator-type properties generally decrease systemic blood pressure, resulting in a reduction in&#x000a0;lower limb&#x000a0;perfusion pressure. These agents may also cause a steal of blood from ischemic regions in which blood vessels&#x000a0;are already maximally dilated. Therefore, there have been questions regarding the&#x000a0;justification for treatment with vasodilators in claudication with absolute contraindication in patients with a history of heart failure. Phosphodiesterase inhibitors have demonstrated decreased survival compared with placebo in patients with class III to IV heart failure. Patients with a history of ischemic heart disease may incur an increased risk of angina pectoris or myocardial infarction exacerbation.<xref ref-type="bibr" rid="article-41826.r22">[22]</xref>&#x000a0;Thus, cilostazol is contraindicated in these populations.</p>
        <p>Caution is also necessary when prescribing cilostazol to individuals with atrial or ventricular ectopy and those with atrial fibrillation or flutter.&#x000a0;Left ventricular outflow tract obstruction is another observation in patients with sigmoid-shaped interventricular septums undergoing cilostazol therapy.<xref ref-type="bibr" rid="article-41826.r23">[23]</xref></p>
      </sec>
      <sec id="article-41826.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients with an increased risk for serious cardiac events&#x000a0;due to increased heart rate (patients with stable coronary disease) require close monitoring during treatment with cilostazol. Patients also need monitoring for bleeding episodes and easy bruising or other signs such as pyrexia and sore throat, suggesting the early development of blood dyscrasia. A&#x000a0;complete blood count is necessary if a&#x000a0;suspected infection or other clinical evidence suggests blood dyscrasia. If the patient shows any clinical or laboratory evidence of a hematologic abnormality, cilostazol therapy should be discontinued immediately.</p>
        <p>Caution is necessary when co-administering cilostazol with any other pharmacologic agent that can reduce blood pressure due to the possibility of an additive hypotensive effect with reflex tachycardia. Dual administration of&#x000a0;cilostazol with&#x000a0;other&#x000a0;antiplatelet&#x000a0;drugs also requires caution as there is a risk for spontaneous, prolonged, or excessive&#x000a0;bleeding.<xref ref-type="bibr" rid="article-41826.r24">[24]</xref></p>
      </sec>
      <sec id="article-41826.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The oral lethal dose of cilostazol is over 5 g/kg in rats and mice and more than 2 g/kg in dogs. There is a lack of data on acute overdosage with cilostazol in humans. The signs and symptoms of an acute cilostazol overdose can present as a severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmia. In an overdose, patients require careful observation and provide supportive treatment. Cilostazol is highly protein-bound and unlikely to be efficiently removed by hemodialysis or peritoneal dialysis. Emptying the stomach by gastric lavage may be appropriate if needed.<xref ref-type="bibr" rid="article-41826.r25">[25]</xref></p>
      </sec>
      <sec id="article-41826.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare professionals such as specialists, nurse practitioners, physician assistants, and physicians who plan to prescribe cilostazol should possess full knowledge regarding the indications and contraindications of the drug. Cilostazol's primary use is treating intermittent claudication, which typically correlates with early-stage peripheral&#x000a0;artery disease.<xref ref-type="bibr" rid="article-41826.r26">[26]</xref></p>
        <p>Prescribing clinicians (MDs, DOs, NPs, PAs) should know that the drug is usually administered twice daily as a 100 mg oral dose&#x000a0;shortly before or after meals. Consider possible&#x000a0;adverse side&#x000a0;effects when using cilostazol in patients with supraventricular arrhythmias or a history of heart disease. Additionally, exercise caution when co-administering cilostazol with any other pharmacologic agent that&#x000a0;may reduce blood pressure due to an additive hypotensive effect&#x000a0;and subsequent reflex tachycardia; therefore, pharmacists should watch for these potential drug interactions and report back to the prescribing clinicians. Both pharmacists and nurses can counsel patients on optimal dosing and possible adverse reactions.</p>
        <p>Patients receiving&#x000a0;cilostazol should be closely monitored for tachyarrythmias, hypotension, and signs of blood dyscrasia, which will primarily be a function of nurses and report these findings to the prescribing clinician. The interprofessional health care team&#x000a0;should work collaboratively to ensure patients taking cilostazol obtain regular follow-ups. The specialty medical professionals should weigh in as needed in the care of these patients for optimal healthcare outcomes. [Level 5]</p>
      </sec>
      <sec id="article-41826.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41826&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41826">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41826/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41826">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-41826.s11">
        <title>References</title>
        <ref id="article-41826.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorkin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Markham</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cilostazol.</article-title>
            <source>Drugs Aging</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-71; discussion 72-3</page-range>
            <pub-id pub-id-type="pmid">10069409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Gerhard-Herman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gornik</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barshes</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Corriere</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Drachman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Fowkes</surname>
                <given-names>FGR</given-names>
              </name>
              <name>
                <surname>Hamburg</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Kinlay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lookstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Misra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mureebe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>RAG</given-names>
              </name>
              <name>
                <surname>Regensteiner</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Schanzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shishehbor</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Treat-Jacobson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>ME</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ikonomidis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pressler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wijeysundera</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary.</article-title>
            <source>Vasc Med</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>NP1</fpage>
            <page-range>NP1-NP43</page-range>
            <pub-id pub-id-type="pmid">28494710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niu</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.</article-title>
            <source>BMJ Open</source>
            <year>2016</year>
            <month>Mar</month>
            <day>17</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>e009013</fpage>
            <pub-id pub-id-type="pmid">26988347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of cilostazol in patients with acute coronary syndrome after percutaneous coronary intervention.</article-title>
            <source>Am J Ther</source>
            <year>2013</year>
            <season>Mar-Apr</season>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-3</page-range>
            <pub-id pub-id-type="pmid">22975664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Degerman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Manganiello</surname>
                <given-names>VC</given-names>
              </name>
            </person-group>
            <article-title>Cyclic nucleotide phosphodiesterase 3 signaling complexes.</article-title>
            <source>Horm Metab Res</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>10</issue>
            <fpage>776</fpage>
            <page-range>776-85</page-range>
            <pub-id pub-id-type="pmid">22692928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shattil</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kashiwagi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pampori</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Integrin signaling: the platelet paradigm.</article-title>
            <source>Blood</source>
            <year>1998</year>
            <month>Apr</month>
            <day>15</day>
            <volume>91</volume>
            <issue>8</issue>
            <fpage>2645</fpage>
            <page-range>2645-57</page-range>
            <pub-id pub-id-type="pmid">9531572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Latif</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle.</article-title>
            <source>Exp Biol Med (Maywood)</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>226</volume>
            <issue>3</issue>
            <fpage>153</fpage>
            <page-range>153-63</page-range>
            <pub-id pub-id-type="pmid">11361033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okagaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kohama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Structure and function of smooth muscle myosin light chain kinase.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>1998</year>
            <volume>453</volume>
            <fpage>229</fpage>
            <page-range>229-34</page-range>
            <pub-id pub-id-type="pmid">9889833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elam</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Heckman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crouse</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hunninghake</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Herd</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Bortey</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>1942</fpage>
            <page-range>1942-7</page-range>
            <pub-id pub-id-type="pmid">9848888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bj&#x000f6;rnsson</surname>
                <given-names>OG</given-names>
              </name>
              <name>
                <surname>Sparks</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sparks</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinases.</article-title>
            <source>Eur J Clin Invest</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-48</page-range>
            <pub-id pub-id-type="pmid">8206083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motoyashiki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ueki</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Involvement of the rapid increase in cAMP content in the vanadate-stimulated release of lipoprotein lipase activity from rat fat pads.</article-title>
            <source>Biol Pharm Bull</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>1412</fpage>
            <page-range>1412-6</page-range>
            <pub-id pub-id-type="pmid">8951155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1999</year>
            <volume>37 Suppl 2</volume>
            <fpage>13</fpage>
            <page-range>13-23</page-range>
            <pub-id pub-id-type="pmid">10702883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Cilostazol: a review of its use in intermittent claudication.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2003</year>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-38</page-range>
            <pub-id pub-id-type="pmid">14727939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reilly</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Mohler</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Cilostazol: treatment of intermittent claudication.</article-title>
            <source>Ann Pharmacother</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-56</page-range>
            <pub-id pub-id-type="pmid">11197586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>KI</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>246</fpage>
            <page-range>246-52</page-range>
            <pub-id pub-id-type="pmid">11956507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guyatt</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutterman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Schu&#x000fc;nemann</surname>
                <given-names>HJ</given-names>
              </name>
              <collab>American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel</collab>
            </person-group>
            <article-title>Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>7S</fpage>
            <page-range>7S-47S</page-range>
            <pub-id pub-id-type="pmid">22315257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Cilostazol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>6</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31260229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Oliphant</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Finks</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and safety of cilostazol: a critical review of the literature.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>377</fpage>
            <page-range>377-95</page-range>
            <pub-id pub-id-type="pmid">25758742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toklu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>DiNicolantonio</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Croce</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Feit</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials.</article-title>
            <source>Open Heart</source>
            <year>2014</year>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>e000068</fpage>
            <pub-id pub-id-type="pmid">25332804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Cilostazol</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>12</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chi</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Lavie</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Milani</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of cilostazol in the management of intermittent claudication.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2008</year>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>1197</fpage>
            <page-range>1197-203</page-range>
            <pub-id pub-id-type="pmid">19337533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carver</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rodeheffer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ivanhoe</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>DiBianco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zeldis</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hendrix</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Bommer</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Elkayam</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kukin</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.</article-title>
            <source>N Engl J Med</source>
            <year>1991</year>
            <month>Nov</month>
            <day>21</day>
            <volume>325</volume>
            <issue>21</issue>
            <fpage>1468</fpage>
            <page-range>1468-75</page-range>
            <pub-id pub-id-type="pmid">1944425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umazume</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Funabashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of cilostazol on left ventricular function in a patient with a sigmoid shaped interventricular septum.</article-title>
            <source>Int J Cardiol</source>
            <year>2013</year>
            <month>May</month>
            <day>25</day>
            <volume>165</volume>
            <issue>3</issue>
            <fpage>551</fpage>
            <page-range>551-5</page-range>
            <pub-id pub-id-type="pmid">22995418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uchiyama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Antiplatelet therapy: update in secondary stroke prevention].</article-title>
            <source>Brain Nerve</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>7</issue>
            <fpage>771</fpage>
            <page-range>771-82</page-range>
            <pub-id pub-id-type="pmid">23832980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frontera</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lewin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Aisiku</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Alexandrov</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>del Zoppo</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Peerschke</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Stiefel</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Teitelbaum</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wartenberg</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Zerfoss</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.</article-title>
            <source>Neurocrit Care</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-46</page-range>
            <pub-id pub-id-type="pmid">26714677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41826.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pressler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Apr</month>
            <day>02</day>
            <volume>127</volume>
            <issue>13</issue>
            <fpage>1425</fpage>
            <page-range>1425-43</page-range>
            <pub-id pub-id-type="pmid">23457117</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
